Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag + rhTPO in Severe ITP
NCT05328804Phase 3Unknown
- Start
- Jan 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hetrombopag in immune thrombocytopenia (ITP). Status: unknown.
02
Drugs
hetrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05328804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328804.